昊海生物科技(06826.HK)中期歸母淨利同比增加739.25%至2.31億元
格隆匯8月26日丨昊海生物科技(06826.HK)公吿,截至2021年6月30日止6個月業績,收入人民幣8.5億元(單位下同),同比增加72%;母公司擁有人應占利潤2.31億元,同比增加739.25%;每股盈利1.31元。
報吿期內,集團營業收入較上年同期增長71.63%,主要繫上年同期集團業務受到全球新冠肺炎疫情影響較為嚴重,而報吿期內疫情影響已逐漸減弱,集團各項業務均已全面恢復並實現大幅增長。
報吿期內,歸屬於上市公司股東的淨利潤較上年同期增長739.25%,主要系營業收入增長及整體毛利率相對穩定帶來的毛利增長所致,同時,報吿期內集團各項費用支出整體與上年同期相比保持穩定。
在白內障領域,集團是國際領先的人工晶狀體廠商,已構建完整的人工晶狀體產業鏈,擁有涵蓋各主要材質、光學設計及附加功能品類的全系列人工晶狀體產品組合,人工晶狀體年銷售數量約佔中國市場使用量的30%。眼科粘彈劑是一種被廣泛應用於白內障、青光眼等多種眼內手術的重要軟性醫用耗材,集團生產的眼科粘彈劑產品國內市場份額連續多年位居市場首位,是國內第一大眼科粘彈劑生產商。
集團是國內知名玻尿酸生產商之一,自主研發掌握了單相交聯、低温二次交聯、線性無顆粒化交聯以及有機交聯等交聯工藝。第一代玻尿酸產品“海薇”是國內首個獲得國家藥監局批准的單相交聯注射用透明質酸鈉凝膠,主要定位於大眾普及入門型玻尿酸。第二代玻尿酸產品“姣蘭”主要市場定位為中高端玻尿酸,主打動態填充功能的特性,第三代玻尿酸產品“海魅”具有線性無顆粒特徵,市場定位為高端玻尿酸,主打“精準雕飾”功能。第四代有機交聯玻尿酸產品的臨牀試驗正在有序開展。集團玻尿酸產品組合已得到市場的廣泛認可,是國產注射用玻尿酸產品的領導品牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.